LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Kodu・Aktsiate loetelu・Xencor Inc

Xencor Inc

Suletud

SektorTervishoid

14.87 6.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.77

Max

15.01

Põhinäitajad
By Trading Economics
Sissetulek	25M -6M
Müük	11M 44M
Kasumimarginaal	-13.821
Töötajad	250
EBITDA	17M -20M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+60.75% upside

Turustatistika
By TradingEconomics
Turukapital	-13M 981M
Eelmine avamishind	8.43
Eelmine sulgemishind	14.87

Uudiste sentiment

By Acuity

50%

160 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

7.87 / 10.84 Toetus ja vastupanu

Xencor Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 17:45 UTC

Tulu

Suurimad hinnamuutused turgudel

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. nov 2025, 17:31 UTC

Tulu

Suurimad hinnamuutused turgudel

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15. nov 2025, 18:03 UTC

Tulu

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15. nov 2025, 15:43 UTC

Tulu

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15. nov 2025, 12:00 UTC

Tulu

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15. nov 2025, 09:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

15. nov 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15. nov 2025, 00:08 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14. nov 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. nov 2025, 22:35 UTC

Tulu

Omandamised, ülevõtmised, äriostud

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. nov 2025, 22:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. nov 2025, 22:29 UTC

Tulu

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. nov 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

14. nov 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. nov 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. nov 2025, 19:29 UTC

Market Talk

Tulu

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. nov 2025, 18:44 UTC

Market Talk

Tulu

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

14. nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xencor Inc Prognoos

Hinnasiht

By TipRanks

60.75% tõus

12 kuu keskmine prognoos

Keskmine 24 USD 60.75%

Kõrge 42 USD

Madal 6 USD

Põhineb 11 Wall Streeti analüütiku instrumendi Xencor Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Xencor Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

7.87 / 10.84Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

160 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.